Skip to main content

Journal of Cancer Research and Clinical Oncology

Ausgabe 1/2016

Inhalt (35 Artikel)

Original Article – Cancer Research

Androgens enhance the glycolytic metabolism and lactate export in prostate cancer cells by modulating the expression of GLUT1, GLUT3, PFK, LDH and MCT4 genes

Cátia V. Vaz, Ricardo Marques, Marco G. Alves, Pedro F. Oliveira, José E. Cavaco, Cláudio J. Maia, Sílvia Socorro

Original Article – Cancer Research

Reverse chemomodulatory effects of the SIRT1 activators resveratrol and SRT1720 in Ewing’s sarcoma cells: resveratrol suppresses and SRT1720 enhances etoposide- and vincristine-induced anticancer activity

Jürgen Sonnemann, Melanie Kahl, Priyanka M. Siranjeevi, Annelie Blumrich, Lisa Blümel, Sabine Becker, Susan Wittig, René Winkler, Oliver H. Krämer, James F. Beck

Original Article – Cancer Research

Expression of activation-induced cytidine deaminase is associated with a poor prognosis of diffuse large B cell lymphoma patients treated with CHOP-based chemotherapy

Kiyoko Kawamura, Akihiko Wada, Ji-Yang Wang, Quanhai Li, Akihiro Ishii, Hideki Tsujimura, Toshiyuki Takagi, Makiko Itami, Yuji Tada, Koichiro Tatsumi, Hideaki Shimada, Kenzo Hiroshima, Masatoshi Tagawa

Original Article – Cancer Research

Drastic morphological and molecular differences between lymph node micrometastatic tumors and macrometastatic tumors of lung adenocarcinoma

Nao Aramaki, Genichiro Ishii, Eiji Yamada, Masahiro Morise, Keiju Aokage, Motohiro Kojima, Tomoyuki Hishida, Junji Yoshida, Norihiko Ikeda, Masahiro Tsuboi, Atsushi Ochiai

Open Access Original Article – Cancer Research

Role of dihydrotestosterone (DHT) on TGF-β1 signaling pathway in epithelial ovarian cancer cells

Karla Kohan-Ivani, Fernando Gabler, Alberto Selman, Margarita Vega, Carmen Romero

Original Article – Cancer Research

Loss of fatty acid synthase suppresses the malignant phenotype of colorectal cancer cells by down-regulating energy metabolism and mTOR signaling pathway

Ligong Chang, Peng Wu, Ravichandran Senthilkumar, Xiaoqiang Tian, Hui Liu, Xia Shen, Zijian Tao, Peilin Huang

Original Article – Cancer Research

How staging of thin melanoma is changed after the introduction of TNM 7th edition: a population-based analysis

A. Caldarella, L. Fancelli, G. Manneschi, A. Chiarugi, P. Nardini, E. Crocetti

Original Article – Cancer Research

miR-181a promotes G1/S transition and cell proliferation in pediatric acute myeloid leukemia by targeting ATM

Xiaodan Liu, Wang Liao, Hongxia Peng, Xuequn Luo, Ziyan Luo, Hua Jiang, Ling Xu

Original Article – Cancer Research

Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549–BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification

Midea Gierke, Jan Sperveslage, David Schwab, Rudi Beschorner, Martin Ebinger, Martin U. Schuhmann, Jens Schittenhelm

Original Article – Cancer Research

Morphological and molecular features of oral fluid-derived exosomes: oral cancer patients versus healthy individuals

Ayelet Zlotogorski-Hurvitz, Dan Dayan, Gavriel Chaushu, Tuula Salo, Marilena Vered

Original Article – Cancer Research

Fusion with human lung cancer cells elongates the life span of human umbilical endothelial cells and enhances the anti-tumor immunity

Xiyan Mu, Chunju Fang, Jing Zhou, Yufeng Xi, Li Zhang, Yuquan Wei, Tao Yi, Yang Wu, Xia Zhao

Original Article – Cancer Research

Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target

Min Joung Lee, Namju Kim, Ho-Kyung Choung, Ji-Young Choe, Sang In Khwarg, Ji Eun Kim

Original Article – Cancer Research

Riproximin modulates multiple signaling cascades leading to cytostatic and apoptotic effects in human breast cancer cells

Asim Pervaiz, Michael Zepp, Hassan Adwan, Martin R. Berger

Original Article – Cancer Research

Replication analysis confirms the association of several variants with acute myeloid leukemia in Chinese population

Songyu Cao, Guohua Yang, Juan Zhang, Yunfeng Shen, Hongxia Ma, Xifeng Qian, Zhibin Hu

Original Article – Cancer Research

Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer

Ji-Won Kim, Debora K. Kim, Ahrum Min, Kyung-Hun Lee, Hyun-Jin Nam, Jee Hyun Kim, Jin-Soo Kim, Tae-Yong Kim, Seock-Ah Im, In Ae Park

Original Article – Cancer Research

Valproic acid (VPA) inhibits the epithelial–mesenchymal transition in prostate carcinoma via the dual suppression of SMAD4

Xiaopeng Lan, Guoliang Lu, Chuanwei Yuan, Shaowei Mao, Wei Jiang, Yougen Chen, Xunbo Jin, Qinghua Xia

Original Article – Cancer Research

Comparing RECIST with EORTC criteria in metastatic bladder cancer

Hakan Öztürk

Original Article – Cancer Research

Prevalence and number of circulating tumour cells and microemboli at diagnosis of advanced NSCLC

Mario Mascalchi, Massimo Falchini, Cristina Maddau, Francesca Salvianti, Marco Nistri, Elena Bertelli, Lapo Sali, Stefania Zuccherelli, Alessandra Vella, Marzia Matucci, Luca Voltolini, Andrea Lopes Pegna, Michaela Luconi, Pamela Pinzani, Mario Pazzagli

Original Article – Cancer Research

Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness?

Francesca Carozzi, Lara Tamburrino, Simonetta Bisanzi, Sara Marchiani, Milena Paglierani, Simonetta Di Lollo, Emanuele Crocetti, Carlotta Buzzoni, Elena Burroni, Luana Greco, Elisabetta Baldi, Cristina Sani

Original Article – Cancer Research

MiR-345 suppresses proliferation, migration and invasion by targeting Smad1 in human prostate cancer

Qi-guang Chen, Wei Zhou, Tao Han, Shu-qi Du, Zhen-hua Li, Zhe Zhang, Guang-yi Shan, Chui-ze Kong

Open Access Original Article – Cancer Research

CITED4 gene silencing in colorectal cancer cells modulates adherens/tight junction gene expression and reduces cell proliferation

Michael A. Rogers, Verena Kalter, Gemma Marcias, Marc Zapatka, Sebastian Barbus, Peter Lichter

Original Article – Cancer Research

TGF-β1-induced miR-202 mediates drug resistance by inhibiting apoptosis in human osteosarcoma

Zaijun Lin, Dianwen Song, Haifeng Wei, Xinghai Yang, Tielong Liu, Wangjun Yan, Jianru Xiao

Original Article – Clinical Oncology

Systemic lupus erythematosus and malignancies risk

Song Mao, Hua Shen, Jianhua Zhang

Original Article – Clinical Oncology

Retinoic acid-related orphan receptor C isoform 2 expression and its prognostic significance for non-small cell lung cancer

Qi Huang, Jinshuo Fan, Xin Qian, Zhilei Lv, Xiuxiu Zhang, Jieli Han, Feng Wu, Caiyun Chen, Jiao Du, Mengfei Guo, Guorong Hu, Yang Jin

Original Article – Clinical Oncology

Impact of functional germline variants and a deletion polymorphism in APOBEC3A and APOBEC3B on breast cancer risk and survival in a Swedish study population

Stella Göhler, Miguel Inacio Da Silva Filho, Robert Johansson, Kerstin Enquist-Olsson, Roger Henriksson, Kari Hemminki, Per Lenner, Asta Försti

Original Article – Clinical Oncology

The impact of adjuvant radiotherapy on radically resected T3 esophageal squamous cell carcinoma

Shao-bin Chen, Hong-rui Weng, Geng Wang, Di-tian Liu, Hua Li, Hao Zhang, Yu-ping Chen

Original Article - Clinical Oncology

The risk of female malignancies after fertility treatments: a cohort study with 25-year follow-up

R. Kessous, E. Davidson, M. Meirovitz, R. Sergienko, E. Sheiner

Original Article – Clinical Oncology

Predictive factors for long-term survival in head and neck squamous cell carcinoma patients with distant metastasis after initial definitive treatment

Ho-Seob Kang, Jong-Lyel Roh, Min-Ju Kim, Kyung-Ja Cho, Sang-wook Lee, Sung-Bae Kim, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon Kim

Original Article – Clinical Oncology

Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO)

C. Kahl, R. Krahl, C. Becker, H. K. Al-Ali, H. G. Sayer, A. Schulze, M. Herold, M. Hänel, S. Scholl, A. Hochhaus, L. Uharek, G. Maschmeyer, D. Haehling, C. Junghanß, N. Peter, D. Kämpfe, E. Kettner, T. Heinicke, T. Fischer, U. Kreibich, H.-H. Wolf, D. Niederwieser

Original Article – Clinical Oncology

Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation

Christian Pfrepper, Anne Klink, Gerhard Behre, Thomas Schenk, Georg-Nikolaus Franke, Madlen Jentzsch, Sebastian Schwind, Haifa-Kathrin Al-Ali, Andreas Hochhaus, Dietger Niederwieser, Herbert Gottfried Sayer

Original Article – Clinical Oncology

Comparison of nine prognostic scores in patients with brain metastases of breast cancer receiving radiotherapy of the brain

Elena Laakmann, Kerstin Riecke, Yvonne Goy, Jan F. Kersten, Andreas Krüll, Volkmar Müller, Cordula Petersen, Isabell Witzel

Original Article – Clinical Oncology

Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea

Se Ik Kim, Myong Cheol Lim, Dong Ock Lee, Sun-Young Kong, Sang-Soo Seo, Sokbom Kang, Eun Sook Lee, Sang-Yoon Park

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.